Stock · WST · Healthcare
United States · Large Cap · listed since 1978 · Revenue 12 mo. $3.3B
Price as of 11/06/2026
West Pharmaceutical Services, Inc. designs, manufactures, and sells containment and delivery systems for injectable drugs and healthcare products in the Americas, Europe, the Middle East, Africa, and the Asia Pacific.
West Pharmaceutical Services, Inc. designs, manufactures, and sells containment and delivery systems for injectable drugs and healthcare products in the Americas, Europe, the Middle East, Africa, and the Asia Pacific. It operates in two segments, Proprietary Products and Contract-Manufactured Products. The Proprietary Products segment offers stoppers and seals for injectable packaging systems; syringe and cartridge components, including custom solutions for the needs of injectable drug applications, as well as administration systems that enhance the safe delivery of drugs through advanced reconstitution, mixing, and transfer technologies; and films, coatings, washing, and vision inspection and sterilization processes and services to enhance the quality of packaging products. This segment also provides drug containment solutions in the form of vials, syringes, and cartridges; and self-injection devices; and a range of integrated solutions, including analytical lab services, pre-approval primary packaging support and engineering development, regulatory expertise, and after-sales technical support. This segment serves biologic, generic, and pharmaceutical drug companies. The Contract-Manufactured Products segment is involved in the design, manufacture, and automated assembly of devices used in surgical, diagnostic, ophthalmic, injectable, and other drug delivery systems, as well as consumer products. This segment primarily serves pharmaceutical, diagnostic, and medical device companies. It sells and distributes its products through its sales force and distribution network, contract sales agents, and regional distributors. West Pharmaceutical Services, Inc. was founded in 1923 and is headquartered in Exton, Pennsylvania.
Original text from the data provider
Summary
53.9 of 100
Mean of the six area values. Each area value is the mean of the stock's ranks among the companies in its sector. 50 is the middle of the sector, not a share of companies beaten.
Analysis
What the price requires
If free cash flow stays at €420.8M (2025), it supports €4.7B. The remaining €20.6B of the market value assume it grows 23.5% a year for 10 years and not at all afterwards.
Required FCF growth per year
23.5%
no growth afterwards
Price to operating cash flow 43.0×, above its usual range.
Middle half of 20 quarters: 27.2× to 38.7×, median 34.0×.
Measures only against its own past, not against what the company is worth. Price as of 11/06/2026.
with respect to the priced-in expectation
No indication in the stored figures.
with respect to the priced-in expectation
Since the last quarter
Q1 → Q2 2026
5 more unchanged: Revenue, 12 mo., FCF, 12 mo., Gross margin, EBIT margin, Return on equity
Derivation
Each area value is the average of its metrics' ranks within the sector (0 to 100, 50 is the middle). For metrics where lower is better, the rank is mirrored. The overall value is the average of the area values.
Price as of 11/06/2026.
| Metric | Stock | Sector median | Position in sector |
|---|---|---|---|
| Return on equity | 15.54% | 11.52% | Rank 67 |
| Return on capital (Greenblatt) | 19.50% | 32.55% | Rank 26 |
| EBIT margin | 20.09% | 18.31% | Rank 61 |
| FCF margin | 15.26% | 14.12% | Rank 56 |
| Gross margin | 35.89% | 60.99% | Rank 22 |
| Metric | Stock | Sector median | Position in sector |
|---|---|---|---|
| Revenue growth, 1 year | 6.26% | 8.04% | Rank 42 |
| Earnings growth, 3 years per year | −4.22% | 5.44% | Rank 27 |
| Earnings growth, 5 years per year | 8.26% | 7.00% | Rank 54 |
| Sustainable growth (ROE × retained earnings) | 9.30% | 3.66% | Rank 92 |
| Metric | Stock | Sector median | Position in sector |
|---|---|---|---|
| Earnings yield | 1.70% | 2.90% | Rank 22 |
| FCF yield | 1.66% | 3.63% | Rank 20 |
| EV/saleslower is better | 9.04 | 4.03 | Rank 18 |
| EV/EBITlower is better | 45.03 | 21.73 | Rank 10 |
| Metric | Stock | Sector median | Position in sector |
|---|---|---|---|
| Share price, 1 year | 35.60% | 8.66% | Rank 81 |
| Share price, 6 months | 23.15% | 24.27% | Rank 49 |
| Share price, 3 months | 18.05% | 15.42% | Rank 59 |
| Distance from 52-week high | −4.05% | −7.35% | Rank 64 |
| Metric | Stock | Sector median | Position in sector |
|---|---|---|---|
| Accruals (Sloan)lower is better | 0.63% | 0.30% | Rank 45 |
| Change in share countlower is better | −1.36% | 0.00% | Rank 72 |
| Dividend streak in years | 29 | 10 | Rank 93 |
| Price reaction to results, market-adjusted | 3.28% | 0.05% | Rank 75 |
| Metric | Stock | Sector median | Position in sector |
|---|---|---|---|
| Equity ratio | 74.38% | 48.40% | Rank 85 |
| Net debt/EBITDAlower is better | −0.49 | 1.11 | Rank 76 |
| Debt to equitylower is better | 0.13 | 0.48 | Rank 77 |
| Volatility, 1 yearlower is better | 31.31% | 31.42% | Rank 51 |
Ten years in figures
| Year | Revenue, $B | EBIT margin | FCF, $M | Shares | Net debt, $M |
|---|---|---|---|---|---|
| 2016 | 1.5 | 13.0% | 49.2 | 75.0M | 25.6 |
| 2017 | 1.6 | 14.3% | 132.5 | 75.8M | −38.9 |
| 2018 | 1.7 | 14.8% | 183.9 | 75.4M | −141.3 |
| 2019 | 1.8 | 16.1% | 240.8 | 75.4M | −109.8 |
| 2020 | 2.1 | 19.5% | 298.1 | 75.8M | −289.8 |
| 2021 | 2.8 | 26.8% | 330.6 | 76.3M | −437.3 |
| 2022 | 2.9 | 26.5% | 439.4 | 75.8M | −576.4 |
| 2023 | 3.0 | 24.1% | 414.5 | 75.3M | −544.9 |
| 2024 | 2.9 | 20.6% | 276.4 | 73.7M | −179.3 |
| 2025 | 3.1 | 20.1% | 468.9 | 72.7M | −374.6 |
3 of 7 StockScorer Score rules met · How the score is built
West Pharmaceutical Services Inc mainly meets criteria in the Momentum category. Result from 18 strategies checked.
West Pharmaceutical Services Inc is rated here with the StockScorer Score strategy, the flagship rule set. It compares return and cash-flow metrics with the median of the company's own sector and checks growth and price trend.
3 of 7 rules met
4 of 11 points
Detail data
Excerpt from 18 strategies checked. The full evaluation is visible after a free sign-up.
With a free account, you can see the match across all strategies checked in one complete overview.
Selected fundamental metrics for West Pharmaceutical Services Inc.
| Metric | Stock | Sector |
|---|---|---|
| P/E ratio | 58.9 | 30.0 |
| P/B ratio | 9.2 | 4.8 |
| Return on equity (ROE) | 15.5% | 11.5% |
| Equity ratio | 74.4% | 48.4% |
| Debt-to-equity (D/E) | 0.13 | 0.48 |
| Dividend yield | 0.2% | 1.3% |
How comparable stocks in the same sector score in the StockScorer model.
| Symbol | Company | Rating |
|---|---|---|
| WST | West Pharmaceutical Services Incthis page | |
| RMD | ResMed Inc | High7.3 |
| SOLV | Solventum Corp. | Low3.6 |
| BAX | Baxter International Inc | Low0.9 |
| RGEN | Repligen Corporation | locked |
| COO | The Cooper Companies, Inc | locked |
Signed up in 30 seconds, free.
Learn more about the metrics in the metrics glossary or all rated stocks in the stock overview.
How StockScorer rates every stock is explained on the methodology page.